insitro

insitro is an AI drug discovery company co-founded and led by Daphne Koller — Stanford Professor, Coursera co-founder, and one of the world's foremost machine learning researchers — with the mission of using machine learning to systematically identify new drugs and predict their properties before entering costly clinical trials. The company has raised approximately $800 million from investors including a16z (lead), Google Ventures, Third Rock Ventures, and others, making it one of the best-capitalised private AI drug discovery companies.

In January 2026 insitro launched its TherML (Therapeutic Machine Learning) platform following the acquisition of CombinAbleAI, creating a full-stack, modality-agnostic AI system that can design small molecules, oligonucleotides, antibodies, and other complex biologics within a single unified platform — addressing all major therapeutic modalities through a common ML architecture. The company's approach starts from high-resolution human disease biology: generating integrated multimodal data corpora combining genomics, cellular imaging, transcriptomics, and phenotypic screening, then applying ML to identify genetic drivers, validate targets, and design therapeutics predicted to work in the relevant human biological context.

Eli Lilly expanded its collaboration with insitro in September 2025 to cover advanced ML models predicting pharmacological properties of small molecules, complementing an earlier partnership on siRNA delivery and antibody discovery. Bristol Myers Squibb collaborates on ALS target identification.

insitro's pipeline prioritises metabolic disease and neuroscience.